FMF diagnosis involves genetic confirmation of pathogenic MEFV variants as well as clinical criteria, characterized by recurrent self-limiting attacks of fever, arthritis, serositis, and elevated inflammatory markers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), with variable symptom-free intervals. This evidence concerns the gene CRP and arthritic joint disease.